Obesity has been firmly established as a major risk factor for kidney cancer, particularly renal cell carcinoma (RCC), the most common type of kidney cancer in adults.2 Studies consistently show that the risk of developing RCC increases significantly with higher body mass index (BMI), a measure of body fat based on height and weight. This association holds true across different populations and age groups. In fact, research shows that each 5 kilograms per square metre increase in BMI raises the risk of RCC by roughly 24 to 34 per cent.2
However, interestingly, people who are overweight or obese at the time of kidney cancer diagnosis often have better survival outcomes than those with a normal weight.7 This phenomenon, known as the ‘obesity paradox’, has been observed in multiple studies. Obese patients are more likely to be diagnosed with tumours at an earlier stage. In many cases, they also have longer overall survival.7
The relationship between weight and kidney cancer is more complex than it might first appear. To understand how weight influences both the risk and progression of this disease, it’s helpful to look more closely at how kidney cancer develops, how body fat behaves, and what the latest research says about outcomes, treatment, and prevention.
Kidney cancer refers to malignant tumours, meaning cancerous growths, that originate in the kidneys. The most common type in adults is renal cell carcinoma (RCC), which accounts for about 85 per cent of all kidney cancer cases.2 RCC includes several subtypes, with clear cell RCC – the most common and aggressive form – being the most frequent. Although "kidney cancer" is a broad term, most cases in adults are RCC. Because of this, the two terms are often used to mean the same thing in this context.
Kidney cancer is often discovered by chance during scans or tests done for unrelated health reasons, as it may not cause symptoms in the early stages. When symptoms do appear, they may include: blood in the urine, persistent side or back pain, fatigue, loss of appetite, or unexplained weight loss.3 As the tumour grows, it can impair kidney function and invade nearby tissues. In more advanced cases, it may spread to other organs such as the lungs, liver, bones, or brain.3 This process, known as metastasis, can significantly complicate treatment and lower the chances of survival. Thanks to improved imaging techniques, more cases are now caught at an early stage. However, around 30 per cent of patients are still diagnosed with advanced disease.2
General obesity is usually measured by body mass index (BMI), and abdominal obesity is often measured by waist circumference. Both are linked to an increased risk of kidney cancer. A large Korean cohort study of over 23 million adults found that people with both general and abdominal obesity had a 45% higher risk of developing kidney cancer than those with neither.6 Even modest increases in BMI were associated with a rise in kidney cancer risk.6
Research has identified the reasons behind this link. Obesity can lead to chronic inflammation, insulin resistance, and higher levels of certain hormones and growth factors that may support cell growth and tumour development.4 Fta tissue, especially visceral fat around internal organs, produces substances that affect how cells grow and die. These include promoting angiogenesis (the formation of new blood vessels) and inhibiting apoptosis (programmed cell death), which can support cancer cell growth.4 In addition, obesity may alter the expression of various genes involved in metabolism, immune response, and hormone signalling. These changes can create an environment in the body that supports tumour growth, especially in the kidneys, which are rich in blood vessels and sensitive to changes in metabolism and hormones.4
Recent studies have shown that not all types of body fat affect kidney cancer outcomes in the same way. Visceral fat, which lies deep within the abdomen and surrounds internal organs, is particularly harmful.4 In a study conducted at Washington University, researchers found that individuals assigned female at birth with high levels of visceral fat had significantly shorter survival after a kidney cancer diagnosis compared to those with lower visceral fat. Specifically, half of the individuals assigned female at birth with high visceral fat levels died within three and a half years. In contrast, more than half of those with low visceral fat were still alive 10 years later.
Interestingly, this pattern was not seen in individuals assigned male at birth. This suggests that differences in fat distribution and metabolism between sexes may affect how kidney cancer behaves.5 The study also found that individuals assigned female at birth with both high visceral fat and tumours showing strong activity in sugar metabolism genes had the worst outcomes, surviving an average of only two years after diagnosis.5 These findings suggest a possible interaction between fat metabolism and tumour biology. This may be important when tailoring treatment, especially for individuals assigned female at birth.
A study based on the NIH-AARP Diet and Health Study found that having a higher BMI at ages 18, 35, and 50 was linked to an increased risk of RCC.5 Importantly, those who gained weight later in life and became obese faced a higher risk of both aggressive and fatal forms of the disease. The study also found encouraging evidence: losing weight later in life, especially reducing BMI by at least 10%, was linked to a significantly lower risk of kidney cancer.5
Although obesity clearly increases the risk of kidney cancer, several studies have reported better outcomes in obese patients after diagnosis. One large study looked at over 2,000 patients with clear cell RCC who had surgery. Those who were overweight or obese were less likely to have advanced-stage cancer and had lower rates of dying specifically from kidney cancer.1 Even when taking other health conditions into account, a higher BMI was not linked to worse outcomes and often predicted better survival.
One possible explanation for this paradox involves differences in tumour biology. In obese patients, certain genes involved in fat metabolism, such as fatty acid synthase, were found to be less active compared to those in people of normal weight. This may lead to less aggressive tumour growth in bodies with high nutrient levels.1 The study also found that obese patients with good nutritional health, measured by higher levels of a blood protein called albumin, had the lowest risk of dying from kidney cancer.1
The obesity paradox has also been seen in other conditions such as heart failure and chronic kidney disease.1 In these cases, it is believed that more nutritional reserves and certain metabolic changes may help protect obese individuals during serious illness.
Body weight may also affect how patients respond to kidney cancer treatment. Several studies have shown that obese patients with advanced kidney cancer (metastatic RCC) may respond better to treatment. In particular, those receiving targeted therapies or immune checkpoint inhibitors often have better overall survival compared to normal-weight patients.1 However, BMI is not always the best predictor of treatment outcomes. In some cases, the amount of visceral fat (deep belly fat measured through CT scans) is more closely linked to treatment outcomes than BMI alone. Some studies even report conflicting results, emphasising that more precise measures of fat distribution and nutritional status may be necessary to fully understand how body composition influences treatment success.
Reducing obesity is one of the most effective strategies for preventing kidney cancer.3 Maintaining a healthy weight through a balanced diet, regular exercise, and healthy lifestyle habits remains essential. Even modest weight loss in later adulthood can reduce the risk of kidney cancer (RCC), giving hope to those aiming to lower their risk through realistic, achievable changes.3
Kidney cancer, and particularly renal cell carcinoma, is strongly linked to obesity. Both general and abdominal fat contribute to a higher risk of developing the disease. Although excess weight raises the chance of getting kidney cancer, some studies suggest that obese patients may survive longer after diagnosis, especially if they are well-nourished and have less aggressive tumours. Differences in fat distribution, gender, tumour gene activity, and metabolic profiles all appear to play important roles in shaping outcomes. While the obesity paradox suggests a possible survival benefit for obese patients after diagnosis, it does not change the fact that managing weight is a key strategy for reducing the burden of kidney cancer. Prevention through lifelong healthy habits and continued research into how weight interacts with cancer biology are essential for improving both patient outcomes and public health.
Not necessarily, but it can increase your risk. Obesity is a major risk factor for renal cell carcinoma, and studies show the risk tends to rise with higher BMI. That said, not everyone who is overweight will develop kidney cancer, as other factors like age, genetics, and lifestyle also play a role.
BMI is helpful but not perfect. It doesn’t show where fat is stored in the body, which can affect kidney cancer risk. Visceral fat has been linked to worse outcomes, especially in people assigned female at birth. Tools like waist measurements or medical imaging can offer a clearer risk picture than BMI alone.
Yes. Even weight loss after age 50 can lower the risk of developing kidney cancer. Research shows that reducing BMI by at least 10% can reduce the risk of more aggressive forms of the disease.
Kidney cancer often causes no symptoms in its early stages. When symptoms do appear, they may include blood in the urine, pain in your back or side, fatigue, loss of appetite, or unexplained weight loss. These signs should be checked by a healthcare professional, especially if they last more than a few days.
